首页> 外文OA文献 >The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study
【2h】

The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study

机译:在英国和意大利,老年痴呆症患者服用安全警告对抗精神病药物处方的影响:一项基于人群的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Antipsychotic (AP) drugs are commonly used to manage the behavioural symptoms of dementia. Nevertheless, international (i.e. the European Medicines Agency in Europe) and national (i.e. the Medicines and Healthcare products Regulatory Agency in the UK and the Italian Drug Agency) regulatory agencies issued safety warnings against AP use in dementia in 2004 and 2009. Objective: The aim of this study is to investigate the short- and long-term impact of safety warnings on the use of APs in UK and Italian persons with dementia using two nationwide databases: The Health Improvement Network (THIN) from the UK and the Health Search Database-Cegedim-Strategic Data-Longitudinal Patient Database (HSD-CSD-LPD) from Italy. Methods: We calculated the overall quarterly prevalence of AP use by class and by individual drug in persons with dementia aged ≥65 years and used generalized linear models to explore the effect of the safety warnings. Results: We identified 58,497 and 10,857 individuals aged ≥65 years with dementia from the THIN and HSD-CSD-LPD databases, respectively, over the period 2000–2012. After the 2004 warnings, the use of atypical APs decreased, whereas the use of conventional APs increased, in Italy and the UK until 2009. However, the trend for APs individually showed that the use of risperidone/olanzapine decreased, whereas the use of quetiapine increased in both countries. After the 2009 warnings (until 2012), the use of atypical and conventional APs decreased in the UK (from 11 to 9 and 5 to 3 %, respectively), but such use increased in Italy (from 11 to 18 and 9 to 14 %, respectively). Conclusion: The 2004 warnings led to a reduction in the use of olanzapine and risperidone and increased the use of quetiapine/conventional APs in both countries. From 2009, the use of APs decreased in persons with dementia in the UK but not in Italy. Possible reasons for the difference in AP use between the two countries include a more proactive approach towards reducing the use of APs in the UK than in Italy.
机译:背景:抗精神病药(AP)通常用于管理痴呆的行为症状。尽管如此,国际(即欧洲的欧洲药品管理局)和国家(即英国的药品和保健产品监管局以及意大利药品管理局)监管机构在2004年和2009年发布了针对痴呆患者使用AP的安全警告。这项研究的目的是使用两个全国性的数据库来调查安全警告对英国和意大利痴呆症患者使用AP的短期和长期影响:英国的Health Improvement Network(THIN)和Health Search数据库-Cegedim-策略性数据-纵向患者数据库(HSD-CSD-LPD),来自意大利。方法:我们计算了65岁以上老年痴呆症患者按类别和按药物划分的AP总体使用率,并使用广义线性模型探讨安全警告的作用。结果:在2000-2012年期间,我们分别从THIN和HSD-CSD-LPD数据库中识别出58,497名和65岁以上的65岁以上的痴呆患者。在2004年警告之后,直到2009年,意大利和英国的非典型AP的使用量有所减少,而常规AP的使用量有所增加。但是,AP的趋势表明,利培酮/奥氮平的使用量有所减少,而喹硫平的使用量却有所减少在两个国家都增加了。在2009年警告之后(直到2012年),英国非典型和传统AP的使用率有所下降(分别从11%降到9%和5%到3%),但在意大利这种使用量增加了(从11%升到18%和9%到14% , 分别)。结论:2004年的警告导致这两个国家减少了奥氮平和利培酮的使用,并增加了喹硫平/常规AP的使用。从2009年开始,英国的痴呆症患者使用AP的人数有所减少,但意大利却没有。两国之间使用AP的差异的可能原因包括,与意大利相比,英国在减少AP使用方面采取了更加积极的态度。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号